4.8 Article

Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: A randomized controlled trial

Journal

JOURNAL OF HEPATOLOGY
Volume 60, Issue 5, Pages 962-968

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2014.01.015

Keywords

Cirrhosis; Portal hypertension; Stent dysfunction; Hepatic encephalopathy; Ascites; Hydrothorax; Variceal bleeding prevention

Funding

  1. Innovative Techniques Support Fund of the French Ministry of Health, STIC
  2. Societe Nationale Francaise de Gastroenterologie

Ask authors/readers for more resources

Background & Aims: The first studies comparing covered stents (CS) and bare stents (BS) to achieve Transjugular Intrahepatic Portosystemic Shunt (TIPS) were in favor of CS, but only one randomized study has been performed. Our aim was to compare the primary patency of TIPS performed with CS and BS. Methods: The study was planned as a multicenter, pragmatic (with centers different in size and experience), randomized, single-blinded (with blinding of patients only), parallel group trial. The primary endpoint was TIPS dysfunction defined as either a portocaval gradient >= 12 mmHg, or a stent lumen stenosis >= 50%. A transjugular angiography with portosystemic pressure gradient measurement was scheduled every 6 months after TIPS insertion. Results: 137 patients were randomized: 66 to receive CS, and 71 BS. Patients who were found to have a hepato-cellular carcinoma, or whose procedure was cancelled were excluded, giving a sample of 129 patients (62 vs. 67). Median follow-up for CS and BS were 23.6 and 21.8 months, respectively. Compared to BS, the risk of TIPS dysfunction with CS was 0.60 95% CI [0.38-0.96], (p=0.032). The 2-year rate of shunt dysfunction was 44.0% for CS vs. 63.6% for BS. Early post TIPS complications (22.4% vs. 34.9%), risk of hepatic encephalopathy (0.89 [0.53-1.49]) and 2-year survival (70% vs. 67.5%) did not differ in the two groups. The 2-year cost/patient was 20 k(sic) [15.9-27.5] for CS vs. 23.4 k(sic) [18-37] for BS (p=0.52). Conclusions: CS provided a significant 39% reduction in dysfunction compared to BS. We did not observe any significant difference with regard to hepatic encephalopathy or death. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available